Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.

  title={Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.},
  author={Job Harenberg and Brigitte Haaf and Carl Erik Dempfle and Gerd Stehle and Dieter L. Heene},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  volume={10 2},
In haemodialysis low-molecular-weight (LMW) heparin is increasingly used for anticoagulation. The advantages over unfractionated (UF) heparin are the lower bleeding risk and the lack of influence on lipid metabolism. However, no reliable and rapid method is available so far to control the efficacy and safety of LMW heparin during haemodialysis. The specific anti-factor Xa (aXa) chromogenic substrate assays are laborious and time consuming. In the present study we have compared chromogenic assay… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 20 references

Low molecular weight heparin.

Thrombosis and haemostasis • 1993

Heparin-induced thrombocytopenia.

Australian and New Zealand journal of medicine • 1992

Technik der Hämodialyse Heparin - isierung

D Bundschu, H Kraker
Blutgerinnungsverfahren • 1990

Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis

J Harenberg, K Huck, a. Bratsch H et
Haemostasis 1990; • 1990

Küb1er W. Long term anticoagu1ation with low mo1ecu1ar weight heparin in outpatients with side effects or oral anticoagulants

J Harenberg, G Leber, CE Dempfle, DL Heene, R Zimmermann
Nouv Rev Fr Hemato/ • 1989

Similar Papers

Loading similar papers…